Aster Capital Management’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,078
Closed -$584K – 1323
2026
Q2
$584K Buy
1,078
+1,069
+11,878% +$602K 0.12% 236
2026
Q1
$2.77K Sell
9
-741
-99% -$369K ﹤0.01% 735
2025
Q4
$365K Buy
750
+581
+344% +$271K 0.16% 127
2025
Q3
$70.8K Sell
169
-397
-70% -$134K 0.04% 432
2025
Q2
$163K Sell
566
-1,111
-66% -$332K 0.04% 424
2025
Q1
$537K Buy
1,677
+1,590
+1,828% +$545K 0.1% 274
2024
Q4
$30.7K Sell
87
-852
-91% -$313K 0.01% 566
2024
Q3
$336K Buy
+939
New +$317K 0.07% 246

Other funds holding UTHR

Aster Capital Management's UTHR Position: Q3 2026 in Review

Aster Capital Management sold out of United Therapeutics (UTHR) in Q3 2026, closing a stake of 1,078 shares — an estimated $584K sold.

Aster Capital Management first reported a position in UTHR in Q3 2024 and held it in 8 quarters. The position peaked at $584K in Q2 2026. 841 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Aster Capital Management reported no remaining United Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Aster Capital Management sold 1,078 United Therapeutics shares in Q3 2026, an estimated $584K.
  • Aster Capital Management first reported a position in United Therapeutics in Q3 2024 and held it in 8 quarters.
  • Aster Capital Management's United Therapeutics position peaked at $584K in Q2 2026.
  • 841 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.